Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs
药企巨头的豪赌：谁将主宰减肥市场？

The tussle between the two drugmakers has spread from the boardroom to the courtroom to the corridors of Washington
辉瑞与诺和诺德为争夺生物科技公司Metsera展开激烈竞购，报价飙升至100亿美元。这场交易不仅涉及法庭诉讼和反垄断审查，更触及华盛顿政治圈，凸显减肥药物市场的巨大潜力和激烈竞争。